Aug. 11 Quick Takes: Digital therapeutics play Mahana secures $61M series B
Plus: Reify raises $220M C round for decentralized trial platform, and updates from Biogen, Pfizer-Fera, Astellas and more
A $61 million series B round led by Jazz Venture Partners and Gurnet Point Capital will enable Mahana Therapeutics Inc. to launch its prescription digital therapeutic for irritable bowel syndrome and advance a digital therapeutics pipeline for other chronic diseases. Lead product Mahana IBS is an FDA-cleared digital therapeutic device that delivers a three-month cognitive behavioral therapy program to reduce symptom severity in IBS patients. Main Street Advisors, KKCG, and Lux Capital also participated in the B round.
Reify Health Inc. raised a $220 million series C round led by Coatue Management to expand its StudyTeam and Care Access platforms to accelerate decentralized clinical trial recruitment and enrollment. New investors ICONIQ Growth and Adams Street Partners and existing investors Sierra Ventures and Battery Ventures also participated. ...